Skip to main content

Connective tissue diseases

Sjögren’s syndrome

06-04-2020 | Sjögren’s syndrome | News

Support for further study of leflunomide–hydroxychloroquine for primary Sjögren’s syndrome

Findings from RepurpSS-I, a small phase 2a trial, suggest that leflunomide–hydroxychloroquine combination therapy has a favorable safety profile and gives rise to a clinical response in patients with primary Sjögren’s syndrome.

06-02-2020 | Sjögren’s syndrome | News

ASAP-III rules out abatacept as standard of care in primary Sjögren’s syndrome

Findings from the phase 3 ASAP-III trial indicate that abatacept does not significantly improve disease activity relative to placebo among patients with primary Sjögren’s syndrome.

29-01-2020 | Sjögren’s syndrome | News

Iscalimab shows potential for primary Sjögren’s syndrome

Findings from a phase 2 trial suggest that iscalimab, an anti-CD40 antibody that blocks the CD40–CD154 pathway, warrants further investigation as a treatment option for primary Sjögren’s syndrome.

05-11-2019 | Sjögren’s syndrome | News

EULAR releases recommendations for managing Sjögren’s syndrome

EULAR has issued recommendations for the management of Sjögren’s syndrome with topical and systemic treatments.

01-11-2019 | Infection | News

Burden of opportunistic infections high for patients with polymyositis, dermatomyositis

A 13-year cohort study indicates that systemic rheumatic diseases are associated with an increased incidence of opportunistic infections, and suggests that patients with polymyositis or dermatomyositis have the highest rates.

25-03-2019 | Sjögren’s syndrome | News

Infections tied to increased risk for Sjögren’s syndrome

Individuals with primary Sjögren’s syndrome are almost twice as likely to have experienced an infection requiring hospital care than those without, researchers report.

25-09-2018 | Sjögren’s syndrome | Article

Clinical and immunological features of anti-centromere antibody-positive primary Sjögren’s syndrome

Tsukamoto M, Suzuki K, Takeuchi T. Rheumatol Ther 2018. doi: 10.1007/s40744-018-0126-2

12-09-2018 | Sjögren’s syndrome | News

Primary Sjögren’s syndrome linked to subclinical CVD

Patients with primary Sjögren’s syndrome may have an elevated risk for subclinical cardiovascular disease, researchers report.

Oral microbiome imbalance reported in Sjögren’s syndrome patients

Study results suggest that patients with primary Sjögren’s syndrome, and those with similar symptoms, may experience dysbiosis of the buccal mucosa microbiome.

03-08-2018 | Sjögren’s syndrome | Highlight | News

Oral microbiome imbalance reported in Sjögren’s syndrome patients

Study results suggest that patients with primary Sjögren’s syndrome, and those with similar symptoms, may experience dysbiosis of the buccal mucosa microbiome.

03-08-2018 | Pathophysiology | Review | Article

S100 proteins in rheumatic diseases

Austermann J, Spiekermann C, Roth J. Nat Rev Rheumatol 2018. doi: 10.1038/s41584-018-0058-9

20-07-2018 | Sjögren’s syndrome | Article

Performance of the 2016 ACR-EULAR classification criteria for primary Sjogren’s syndrome in a Korean cohort

Lee J et al. Rheumatol Int 2018. doi: 10.1007/s00296-018-4109-y

02-07-2018 | Vasculitis | Case report | Article

A case report of REM sleep behavior disorder, Behcet’s disease, Sjogren’s syndrome and cognitive dysfunction

The authors report a patient with a history of Behcet’s disease and Sjogren’s syndrome in which rapid eye movement sleep behavior disorder was detected by polysomnographic monitoring.

Xiao F et al. BMC Rheumatol 2018; 2: 19. doi: 10.1186/s41927-018-0022-y

26-05-2018 | Sjögren’s syndrome | Review | Article

Advances in the diagnosis and treatment of Sjogren’s syndrome

Chen X, Wu H, Wei W. Clin Rheumatol 2018. doi: 10.1007/s10067-018-4153-8

07-05-2018 | Cardiovascular disease | Article

Coronary flow reserve in systemic rheumatic diseases: A systematic review and meta-analysis

Erre GL et al. Rheumatol Int 2018; Advance online publication. doi: 10.1007/s00296-018-4039-8

07-02-2018 | Sjögren’s syndrome | News

Epratuzumab may be beneficial for patients with SLE-associated Sjögren’s syndrome

A post-hoc subgroup analysis of the EMBODY trials suggests that systemic lupus erythematosus patients who have associated Sjögren’s syndrome may derive clinical benefit from the CD22-targeted B-cell inhibitor epratuzumab.

07-11-2017 | Sjögren’s syndrome | ACR/ARHP 2017 | News

CD40 blockade shows promise in Sjögren’s syndrome

Phase IIa trial results suggest that treatment with the anti-CD40 monoclonal antibody CFZ533 improves disease activity and is well tolerated in patients with clinically active primary Sjögren’s syndrome.

27-03-2017 | Sjögren’s syndrome | News

Rituximab falls short in Sjögren's syndrome trial

Treatment with two courses of rituximab does not reduce fatigue or oral dryness among patients with primary Sjögren's syndrome, results of the TRACTISS trial suggest.

Image Credits